Last mentioned: Mar 19, 2026
Runway Horizon
Current capital projected to fund operations through significant commercial milestones.
Cash Runway Limit
Current capital projected to fund operations through this period across commercial milestones.
2026 Target
Goal to reach 15-17 states and operate 5-7 live partner programs.
Commercial Target
Goal to reach 15-17 states and 5-7 live partner programs.
Q4 Earnings Call
Management outlines pivot from R&D to commercial scaling and state-level engagement.
Q4 Earnings Call
Management confirms runway through 2028 and details PRIME study impact.
Fiscal Year End
Sera concludes 2025 with $95.8M cash and successful PRIME study publication.
Fiscal Year End
Sera concludes 2025 with $95.8M in cash and a narrowed net loss.
Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. The company is pivoting toward large-scale commercialization of its PreTRM test following landmark PRIME study data showing a 56% reduction in very early preterm births.
Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. Following the successful publication of its PRIME study—which demonstrated a 56% reduction in very preterm births—the company is aggressively shifting its focus toward state-level payer engagement and commercial scaling.